Please Wait...

IGF-1 // Insulin-Like Growth Factor I or Somatomedin C

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Insulin Like Growth Factor 1 (IGF-1) and 2 (IGF-2) are produced mainly by hepatocytes, and to a lesser extent in other tissues (Ranke, 2015). IGF-1 and IGF-2 have structural and sequence homology with insulin and also shared some biological functions. These hormone were assigned in 1978 to the family of somatomedins (Rinderknecht and Humbel, 1978a, 1978b). Higher risks of cancer were found to be associated with high IGF-1 levels in serum. This can be the result of IGF-1 influence on epithelial-cell population renewal rates and of its anti-apoptotic effect (Pollak et al., 2004). IGF-1 circulates as a ternary complex with Acid Labile Subunit (ALS) and IGF-Binding Proteins (IGFBPs) and less than 1% is free. As a direct mediator, non-affected by diurnal fluctuation, serum IGF-1 reflect the levels of Growth Hormone (GH) and is used in the diagnosis of a wide range of diseases arising from GH deficiency or excess (Ketha and Singh, 2015).

Bioclinica Lab employs a manual sandwich radioimmunoassay for measurement of IGF-1 in serum.


Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Still time to catch up on summer reading on recent developments in #Alzheimer's Disease Fluid Biomarkers here int t…
bioclinica (Yesterday)
Our clients have substantial success w #eSource, some spanning well over a decade. Still other organizations remain…
bioclinica (2 days ago)
Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai…
bioclinica (4 days ago)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (1 week ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining…
bioclinica (1 week ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch…
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen